Introduction
============

Atherosclerosis is a chronic inflammatory response of the walls of arteries mainly due to a deregulated lipid metabolism and promoted by the local accumulation of macrophages \[[@B1]\]. In addition to the well known risk factors, including hypertension, diabetes, low-density lipoprotein cholesterol and smoking, increasing evidence suggested that aging is also an important independent risk factor for atherosclerosis, persisting also when other known factors are controlled \[[@B2]\].

Heart-type fatty acid binding protein (H-FABP) is a small intracellular protein involved in the transport of hydrophobic long-chain fatty acids from the cell membrane inside the cells. In addition, it also promotes the expression of different pro-inflammatory cytokines and is a powerful regulator of the mitochondrial beta-oxidative system in the heart \[[@B3],[@B4]\]. A recent study indicated that circulating H-FABP is positive correlated with intima-media thickness and may represent a new possible diagnostic biomarker for early atherosclerosis \[[@B5]\].

Several studies shown that people affected by down syndrome (DS) are relatively resistant to developing atherosclerosis and coronary artery diseases despite the presence of an unfavourable plasma lipid profile and are generally considered an "atheroma-free" model \[[@B6]-[@B8]\].

For these reasons, due to the absence of atherosclerosis in DS, in the present study we aimed to measure H-FABP level both in DS and in healthy subjects during aging to evaluate the association between this molecule, aging and atherosclerosis.

Subjects and methods
--------------------

### Subjects

Three groups of male DS and age-matched healthy subjects were studied: the first consisted of 23 DS and 20 healthy children (age 2--14 years); the second of 14 DS and 20 healthy adults (age 20--50 years); the third group of 13 DS and 20 healthy elderly (\> 60 years). All DS were assessed by clinical examination and karyotype analysis; they had mild and variable degree of mental retardation, no other pathological conditions at the time of the study and were in good health. The project was approved by University of Milan Ethics Committee and by the Fondazione Antoniana of Bologna, Italy.

### FABP assay

Plasma was obtained by centrifugation at 1500 g for 15 min, transferred into coded plastic tubes, rapidly frozen and stored at −20°C until analysis. H-FABP was quantified using a biochip array analyzer (Evidence Invatigator, Randox Ltd., Crumlin, UK). A biochip is a solid substrate supporting an array of discrete test regions, with immobilized antigen-specific antibodies. After an immuno-enzymatic reaction, each spot generates a chemiluminescent signal on the array which is captured by a charge-coupled camera (CCD-camera) and converted by an image processing software to provide results comparable with calibration curves.

### Statistical analysis

The results are given as mean ± standard deviation (SD). Comparison between groups was performed using Student's two-tailed *t* test. A p value \< 0.05 was considered significant. Analyses were performed using GraphPad Software (San Diego, CA).

Results
=======

By comparing DS and healthy subjects groups (age range 2--65 years) we observed lower H-FABP level in DS group (1.13 ± 0.34 ng/mL *vs.* 3.49 ± 0.96 ng/mL; p \< 0.0001) (Figure [1](#F1){ref-type="fig"}).

![**H-FABP level in down syndrome people (DS) compared to healthy subjects (CTR).** H-FABP level was evaluated in DS and in CTR groups (age range 2--65 years). \*p \< 0.0001 *vs.* CTR.](1742-4933-10-2-1){#F1}

Figure [2](#F2){ref-type="fig"} shows that H-FABP level is statistically significantly lower in DS than in age-matched healty subjects (DS children 1.14 ± 0.41 ng/ml *vs.* healthy children 2.71 ± 0.51 ng/ml, p \< 0.001; DS adults 1.11 ± 0.29 ng/ml *vs.* healthy adults 4.11 ± 0.35 ng/ml, p \< 0.001; DS elderly 1.18 ± 0.23 ng/ml *vs.* healthy elderly 5.1 ± 0.15 ng/ml, p \< 0.001).

![**H-FABP level in down syndrome people (DS) and healthy subjects (CTR) classified according to age.** DS and in CTR were subdivided in three groups according to age: the first included children (age 2--14 years); the second adults (age 20--50 years); the third elderly ( \> 60 years). H-FABP was measured in each group and comparison has been performed both between DS and age-matched CTR and between the three DS and CTR age groups. \*p \< 0.001 *vs.* age-matched CTR, °p \< 0.01 *vs.* adults CTR, °° p \< 0.001 *vs.* children CTR.](1742-4933-10-2-2){#F2}

Healthy subjects displayed a trend of increase in H-FABP level with aging (children *vs.* adults p \< 0.001; elderly *vs*. adults p \< 0.01). On the contrary, no difference has been observed in H-FABP level between children, adults and elderly DS (Figure [2](#F2){ref-type="fig"}).

Discussion
==========

The main finding of our study is that aging is normally associated with increased H-FABP level but this is not true in DS which display not only the same level in the different ages of life but have also lower level compared to their age-matched healthy subjects. Our study is in agreement with previous observation which described a striking increase in H-FABP value with aging \[[@B9]\] and, to our knowledge, is also the first comparing circulating H-FABP level in DS and healthy subjects.

The unchanged H-FABP level during aging in DS and the lack of atherosclerosis in these subjects prompted us to consider H-FABP as one potential molecule linking aging and atherosclerosis.

It is well know that aging is associated with reduced cellular proliferative potential, increased propensity to undergo death, elevated DNA damage and, at vascular level, increased expression of pro-inflammatory and leukocyte adhesion molecules and increased uptake of plasma lipoproteins, all key events that ultimately promote atherosclerosis \[[@B2]\]. Although the same mechanisms are present in DS, which also display an accelerated aging process compared to healthy subjects, anyway they resulted protected against atherosclerosis \[[@B10],[@B11]\]. The mechanisms that may be involved in such protective effect are not well known. Anyway, our observation highlighted that reduced H-FABP level may contribute to this general protection.

Our study have some limitations, including the reduced sample size, the lack of correlation with bioclinical parameters and atherosclerosis-related risk factors. For these reasons, our data may be considered preliminary observations which need further investigation to better understand the relationship between H-FABP, atherosclerosis and coronary artery disease.

In conclusion, reduced H-FABP level during aging in DS may play a protective role against atherosclerosis. This observation highlighted a potential involvement of H-FABP in the relationship between aging and atherosclerosis.
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